During the first semester of the financial year 2018/19 we achieved a consolidated totalturnover of CHF 258.7 million (previous year: CHF 213.4 million). This corresponds to an increase of CHF 45.3 million.
Included in the result is a CHF 49.8 million revenue and profit-related compensationfrom Insulet Corp. for setting up the European distribution structure for the Omnipod insulin patch pump. Adjusted for all Omnipod effects, we achieved growth of CHF 16.8 million, an increase of 12.6 %. The operating result (EBIT) amounts to CHF 68.4 million(previous year: CHF 26.9 million) with an EBIT margin of 26.4%. The net profit for thereporting period amounts to CHF 56.1 million (previous year: CHF 23.4 million).
Download reports and fact sheets
On this page you can download all financial publications of Ypsomed Holding AG covering the last five years of business activity. If you prefer a printed copy, please use the order form on this page.